Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06308510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 2026 → Dec 2026
See other at-risk trials from Erasmus Medical Center

Record History

  1. Primary completion pushed from Jul 2026 to Dec 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2024 to Dec 17, 2024 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2024 to Dec 17, 2024
    • Site details revised
  3. Start date: Jul 2024 to Oct 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.
Trial Details
NCT Number NCT06308510
Lead Sponsor Erasmus Medical Center
Conditions Gastric Cancer
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov